1001353-78-1

Basic information

• Product Name: L-Proline, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)aMino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-2-Methyl-
• Synonyms: L-Proline, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)aMino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-2-Methyl-;(S)-1-(4-((5-cyclopropyl-1H-pyrazol-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-2-methylpyrrolidine-2-carboxylic acid
• CAS NO: 1001353-78-1
• Molecular Formula: C18H21N7O2
• Molecular Weight: 367.40504
• Mol File: 1001353-78-1.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: L-Proline, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)aMino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-2-Methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: L-Proline, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)aMino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-2-Methyl-(1001353-78-1)
• EPA Substance Registry System: L-Proline, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)aMino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-2-Methyl-(1001353-78-1)

Safety Data

• Hazardous Substances Data: 1001353-78-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
L-Proline, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-2-Methylis used as a research compound for exploring its potential biological activities and therapeutic applications. Its unique structure and the presence of various functional groups make it a promising candidate for the development of new drugs and therapies.
Used in Drug Design and Development:
In the field of drug design and development, L-Proline, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-2-Methylis utilized as a key component in the synthesis of novel drug molecules. Its versatile structure allows for the creation of various derivatives with potential therapeutic properties, making it a valuable asset in the search for new treatments for various diseases and conditions.
Used in Chemical Synthesis:
L-Proline, 1-[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1-f][1,2,4]triazin-2-yl]-2-Methylis also used in chemical synthesis as a building block for the creation of more complex molecules. Its unique structure and functional groups can be exploited to form new chemical entities with potential applications in various industries, including pharmaceuticals, materials science, and agrochemicals.

Upstream product

• 175137-46-9 3-amino-5-cyclopropyl-1H-pyrazole 
• 159326-69-9 1-aminopyrrole-2-carboxamide 
• 1379337-32-2 1-(ethoxyformamido)-1H-pyrrole-2-carboxamide 
• 918538-05-3 2,4-dichloro-pyrrolo[2,1-f][1,2,4]triazine 
• 918538-04-2 pyrrolo[2,1-f][1,2,4]triazine-2,4(1H, 3H)-dione 
• 918538-08-6 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyrrolo[1,2-f][1,2,4]triazin-4-amine 
• 42856-71-3 (S)-2-methylpyrrolidine-2-carboxylic acid 

Downstream Products

• 1446701-47-8 [18F](S)-1-(4-((5-cyclopropyl-1H-pyrazol-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl)-N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide 

Relevant articles and documents

Discovery of a 2,4-disubstituted pyrrolo-[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development

This report describes the biological activity, characterization, and SAR leading to 9d (BMS-754807) a small molecule IGF-1R kinase inhibitor in clinical development. 2009 American Chemical Society.

Synthesis and in vitro evaluation of [18F]BMS-754807: A potential PET ligand for IGF-1R

Radiosynthesis and in vitro evaluation of [18F](S)-1-(4-((5- cyclopropyl-1H-pyrazol-3-yl)amino)pyrrolo[2,1-f][1,2,4]triazin-2-yl) -N-(6-fluoropyridin-3-yl)-2-methylpyrrolidine-2-carboxamide ([ 18F]BMS-754807 or [18F]1) a specific IGF-1R inhibitor was performed. [18F]1 demonstrated specific binding in vitro to human cancer tissues. Synthesis of reference standard 1 and corresponding bromo derivative (1a), the precursor for radiolabeling were achieved from 2,4-dichloropyrrolo[2,1-f][1,2,4]triazine (4) in three steps with 50% overall yield. The radioproduct was obtained in 8% yield by reacting 1a with [ 18F]TBAF in DMSO at 170 C at high radiochemical purity and specific activity (1-2 Ci/μmol, N = 10). The proof of concept of IGF-IR imaging with [18F]1 was demonstrated by in vitro autoradiography studies using pathologically identified surgically removed grade IV glioblastoma, breast cancer and pancreatic tumor tissues. These studies indicate that [ 18F]1 can be a potential PET tracer for monitoring IGF-1R.

PYRROLOTRIAZINE KINASE INHIBITORS

The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.